NASDAQ$OPK
OPKO Health Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
OPKO Health's financial performance decreased in the second quarter of 2021 due to increased costs and expenses, despite revenue growth.
OPKO Health reported consolidated total revenues of $442.4 million for Q2 2021, compared to $301.2 million for the comparable period in 2020. However, the company experienced a net loss of $16.2 million, or $0.03 per share, compared to net income of $33.7 million, or $0.05 per diluted share, for the same period in 2020. The decrease in profitability was primarily due to increased costs and expenses.
- BioReference Laboratories test volume increased 32% compared with the second quarter of 2020, processing approximately 2.8 million COVID-19 PCR tests.
- OPKO executed an agreement with Nicoya Therapeutics for the development and commercialization of RAYALDEE® in Greater China, receiving an upfront payment of $5 million.
- OPKO executed an exclusive worldwide agreement with CAMP4 Therapeutics Corporation for the development, manufacture and commercialization of therapeutics utilizing the AntagoNAT technology.
- OPKO sold its sterile fill-and-finish manufacturing facility in Ireland to Horizon Therapeutics plc for $65 million.
Headline financials
Revenue & EPS history
OPKO Health · Revenue · Quarterly
$442M
Revenue by segment
OPKO Health · $398M total across 2 segments · Q4 2021
- Services$363M—91.1%
- Products$35.3M—8.9%
Forward guidance
OPKO's senior management will provide a business update, discuss second quarter financial results and answer questions during a conference call and live audio webcast beginning at 4:30 p.m. Eastern time today, July 29, 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
-0.7%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-0.2%
Avg return
30 days after
44%
27 / 61 earnings
Positive
+26.8%
Q1 2018
Best reaction
-17.7%
Q3 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.8% | -8.3% | +19.2% | |
| Q4 2025 | +2.5% | +0.0% | -6.7% | |
| Q3 2025 | -2.9% | -4.3% | -2.9% | |
| Q1 2025 | -2.2% | -7.2% | -1.4% | |
| Q4 2024 | +6.7% | +19.0% | +4.3% | |
| Q3 2024 | +3.4% | +9.5% | +8.2% | |
| Q2 2024 | +6.7% | +11.9% | +16.4% | |
| Q1 2024 | -5.3% | -3.0% | +1.5% | |
| Q4 2023 | -1.1% | -1.0% | +20.0% | |
| Q3 2023 | -0.7% | -6.7% | +18.5% | |
| Q2 2023 | +13.1% | +6.8% | +2.8% | |
| Q1 2023 | +15.0% | +26.5% | -1.4% | |
| Q4 2022 | +0.0% | +7.5% | +22.6% | |
| Q3 2022 | -14.8% | -9.3% | -25.8% | |
| Q2 2022 | -6.6% | +2.9% | -12.7% | |
| Q1 2022 | +11.8% | +15.6% | +8.4% | |
| Q4 2021 | +7.4% | +3.7% | +17.8% | |
| Q3 2021 | +5.9% | +16.2% | +15.4% | |
| Q2 2021 | -11.6% | -7.2% | -0.8% | |
| Q1 2021 | -3.7% | -4.2% | -10.5% | |
| Q4 2020 | -13.6% | -18.0% | -12.9% | |
| Q3 2020 | -12.0% | -11.0% | +3.3% | |
| Q2 2020 | -11.1% | -7.4% | -42.3% | |
| Q1 2020 | -15.2% | +3.9% | +2.2% | |
| Q4 2019 | +3.6% | +12.2% | +0.7% | |
| Q3 2019 | -2.0% | -2.6% | +5.3% | |
| Q2 2019 | -2.1% | -6.2% | -4.6% | |
| Q1 2019 | -16.1% | -14.9% | -22.1% | |
| Q4 2018 | -9.9% | -5.7% | -7.8% | |
| Q3 2018 | +6.7% | -7.4% | -6.0% | |
| Q2 2018 | -0.4% | -1.6% | +1.5% | |
| Q1 2018 | +26.8% | +37.8% | +23.5% | |
| Q4 2017 | -0.6% | +0.9% | -6.5% | |
| Q3 2017 | -17.7% | -20.1% | -20.2% | |
| Q2 2017 | +1.7% | -1.3% | -1.6% | |
| Q1 2017 | -3.4% | -0.8% | -13.7% | |
| Q4 2016 | -11.5% | -9.3% | -4.6% | |
| Q3 2016 | -6.6% | -3.4% | +11.8% | |
| Q2 2016 | +0.3% | -0.5% | -5.1% | |
| Q1 2016 | +6.7% | — | — | |
| Q4 2015 | +0.4% | — | — | |
| Q3 2015 | +7.6% | — | — | |
| Q2 2015 | -13.7% | — | — | |
| Q1 2015 | +4.8% | — | — | |
| Q4 2014 | -2.7% | — | — | |
| Q3 2014 | +2.5% | — | — | |
| Q2 2014 | -4.0% | — | — | |
| Q1 2014 | +8.4% | — | — | |
| Q4 2013 | -0.6% | — | — | |
| Q3 2013 | -1.4% | — | — | |
| Q2 2013 | +3.7% | — | — | |
| Q1 2013 | +3.4% | — | — | |
| Q4 2011 | -4.0% | — | — | |
| Q1 2011 | +1.3% | — | — | |
| Q1 2012 | +2.7% | — | — | |
| Q4 2009 | -2.6% | — | — | |
| Q3 2011 | -2.3% | — | — | |
| Q2 2011 | -3.3% | — | — | |
| Q4 2010 | -3.3% | — | — | |
| Q3 2010 | +0.7% | — | — | |
| Q1 2010 | +9.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro